Brief: Wave Life Sciences Announces Acceptance Of Late-Breaking Oral Presentation On Wve-006 For Alpha-1 Antitrypsin Deficiency At The American Thoracic Society International Conference
05/03/2026 13:34
March 5 (Reuters) - WAVE Life Sciences Ltd WVE.O: WAVE LIFE SCIENCES ANNOUNCES ACCEPTANCE OF LATE-BREAKING ORAL PRESENTATION ON WVE-006 FOR ALPHA-1 ANTITRYPSIN DEFICIENCY AT THE AMERICAN THORACIC SOCIETY INTERNATIONAL CONFERENCE Source text: ID:nGNX16wsr5 Further company coverage: WVE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Wave Life Sciences
See all newsWave Life Sciences Ltd Reports Results For The Quarter Ended June 30: Earnings Summary
Wave Life Sciences Ltd Expected To Post A Loss Of 31 Cents A Share: Earnings Preview
Wave Life Sciences Q1 revenue jumps, beats analyst estimates
Brief: Wave Life Sciences Announces Hearing On Proposed Redomiciliation To The United States
Brief: Wave Life Sciences Announces Proposed Redomiciliation To The United States